XRCC5

X-ray repair cross-complementing protein 5

748 patent compounds predicted against XRCC5, 222 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13346489	0.67	3/20
SCHEMBL30436407	0.67	3/20
SCHEMBL31060848	0.67	3/20
SCHEMBL13346492	0.54	3/20
SCHEMBL31060688	0.54	3/20
SCHEMBL3536668	1.00	2/20
SCHEMBL31060252	1.00	2/20
SCHEMBL7327543	0.71	2/20
SCHEMBL29161388	0.71	2/20
SCHEMBL3542251	0.66	2/20
SCHEMBL13435723	0.66	2/20
SCHEMBL31060404	0.66	2/20
SCHEMBL610237	0.65	2/20
SCHEMBL29374897	0.65	2/20
SCHEMBL30943704	0.65	2/20
SCHEMBL30943705	0.65	2/20
SCHEMBL7320358	0.62	2/20
SCHEMBL7329165	0.59	2/20
SCHEMBL7315961	0.57	2/20
SCHEMBL7320037	0.57	2/20

Germline variants in XRCC5 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full XRCC5 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to XRCC5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma	PHASE1/PHASE2	COMPLETED
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems	PHASE1	WITHDRAWN
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Chromosomal Translocations in Chandigarh Police	nan	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	nan	RECRUITING
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Telomere Repair Gene Mutation in Inflammatory Bowel Disease	nan	COMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a XRCC5 binder may also engage these)

Protein	Name	Similarity
Q6DDS9	—	1.000	Q6DDS9 →
P27641	—	0.994	P27641 →
Q7RX73	—	0.991	Q7RX73 →
Q4WI96	—	0.988	Q4WI96 →
Q2MHH1	—	0.988	Q2MHH1 →
O93257	—	0.987	O93257 →
Q1E6K9	—	0.986	Q1E6K9 →
Q2MHH2	—	0.985	Q2MHH2 →
Q5B4H8	—	0.985	Q5B4H8 →
DNM2	Dynamin-2	0.984	landscape →
P31669	—	0.983	P31669 →
Q6AXM7	—	0.983	Q6AXM7 →
Q2KHZ2	—	0.983	Q2KHZ2 →
Q9SIU2	—	0.983	Q9SIU2 →
Q9NRY4	—	0.983	Q9NRY4 →
F4IQJ2	—	0.983	F4IQJ2 →
Q75IP6	—	0.983	Q75IP6 →
Q5K651	—	0.983	Q5K651 →
Q69ZS7	—	0.983	Q69ZS7 →
Q7SYB2	—	0.982	Q7SYB2 →
Q9YHB5	—	0.982	Q9YHB5 →
Q8C0D5	—	0.982	Q8C0D5 →
Q8R4Z9	—	0.982	Q8R4Z9 →
Q9ERA6	—	0.982	Q9ERA6 →
Q96SY0	—	0.982	Q96SY0 →
Q7SH49	—	0.982	Q7SH49 →
Q86T65	—	0.982	Q86T65 →
O13046	—	0.982	O13046 →
Q5ZJM3	—	0.982	Q5ZJM3 →
E9Q735	—	0.982	E9Q735 →